VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
ALNY
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
ALNYAlnylam Pharmaceuticals, Inc.
$143.82$19.2B
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
HomeStocksALNYFinancials

Alnylam Pharmaceuticals, Inc. (ALNY) Income Statement

24Y historyFree accessUpdated daily

Revenue climbed from about $594M in 2025Q1 to roughly $1.5B in 2026Q3 with gross margins of 75% to 88%, but operating margin swung from -17.7% to 29.5%, indicating that gross profit strength has not yet translated into stable bottom-line results.

Income StatementBalance SheetCash FlowRatios

ALNY Income Statement

Annual statement

ALNY Income Statement

Alnylam Pharmaceuticals, Inc. (ALNY) annual income statement — 24-year revenue, gross profit & net income history

AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10Dec'09Dec'08Dec'07Dec'06Dec'05Dec'04Dec'03Dec'02
Sales/Revenue5.01B3.71B2.25B1.83B1.04B844.29M492.85M219.75M74.91M89.91M47.16M41.1M50.56M47.17M66.72M82.76M100.04M100.53M96.16M50.9M26.93M5.72M4.28M176K0
Revenue Growth %56.17%65.19%22.97%76.23%22.88%71.31%124.28%193.36%-16.69%90.66%14.75%-18.72%7.2%-29.31%-19.37%-17.28%-0.49%4.54%88.94%89%371.13%33.61%2330.68%--
Cost of Goods Sold1.14B677.17M323.37M310.41M168.82M140.14M78.05M25.06M1.8M13.37M000000000000000
COGS % of Revenue-18.23%14.38%16.98%16.27%16.6%15.84%11.4%2.41%14.87%---------------
Gross Profit3.87B3.04B1.92B1.52B868.6M704.14M414.8M194.69M73.11M76.55M47.16M41.1M50.56M47.17M66.72M82.76M100.04M100.53M96.16M50.9M26.93M5.72M4.28M176K0
Gross Margin %77.28%81.77%85.62%83.02%83.73%83.4%84.16%88.6%97.59%85.13%100%100%100%100%100%100%100%100%100%100%100%100%100%100%-
Gross Profit Growth %-57.76%26.81%74.75%23.36%69.75%113.06%166.31%-4.49%62.31%14.75%-18.72%7.2%-29.31%-19.37%-17.28%-0.49%4.54%88.94%89%371.13%33.61%2330.68%--
Operating Expenses2.9B2.54B2.1B1.8B1.65B1.41B1.24B1.13B887.78M590M471.75M337.11M234.78M140.11M131.18M137.57M144.11M148.64M124M144.07M66.43M49.19M36.54M20.62M4.22M
OpEx % of Revenue-68.26%93.48%98.46%159.4%167.34%252.25%516.1%1185.16%656.2%1000.33%820.27%464.34%297.05%196.6%166.24%144.05%147.86%128.95%283.07%246.68%860.53%854.18%11718.18%-
Selling, General & Admin1.34B1.21B975.53M795.65M770.66M620.64M588.42M479M382.36M199.37M89.35M60.61M44.53M27.15M44.61M38.28M37.73M39.91M27.11M23.39M16.63M13.87M11.94M7.53M880K
SG&A % of Revenue-32.6%43.39%43.52%74.29%73.51%119.39%217.98%510.44%221.73%189.47%147.48%88.06%57.57%66.86%46.26%37.71%39.7%28.2%45.95%61.76%242.63%279.08%4276.7%-
Research & Development1.56B1.32B1.13B1B883.01M792.16M654.82M655.11M505.42M390.63M382.39M276.5M190.25M112.96M86.57M99.3M106.38M108.73M96.88M120.69M49.8M35.32M24.6M13.1M3.34M
R&D % of Revenue-35.66%50.09%54.94%85.12%93.83%132.86%298.12%674.72%434.46%810.86%672.79%376.28%239.48%129.74%119.98%106.34%108.15%100.75%237.12%184.92%617.9%575.11%7441.48%-
Other Operating Expenses190K0000-2.05M004.17M-3.02M076K1.82M-47K331K0000000000
Operating Income977.59M501.58M-176.88M-282.18M-785.07M-708.65M-828.44M-939.43M-814.67M-500.09M-424.59M-296.01M-404.98M-92.94M-129.46M-54.82M-44.07M-48.11M-27.84M-93.18M-39.5M-43.47M-32.26M-25.06M-4.22M
Operating Margin %19.5%13.51%-7.87%-15.43%-75.68%-83.94%-168.09%-427.5%-1087.56%-556.2%-900.33%-720.27%-800.97%-197.05%-194.01%-66.24%-44.05%-47.86%-28.95%-183.07%-146.68%-760.53%-754.18%-14236.93%-
Operating Income Growth %-383.56%37.31%64.06%-10.78%14.46%11.81%-15.31%-62.91%-17.78%-43.44%26.91%-335.73%28.21%-136.16%-24.39%8.4%-72.84%70.13%-135.89%9.13%-34.74%-28.76%-493.49%-
EBITDA1.03B557.24M-120.22M-228.12M-740.6M-661.09M-754M-885.06M-808.24M-486.72M-409.46M-276.96M-393.05M-82.71M-120.42M-49.69M-39.13M-42.12M-22.11M-89.09M-35.69M-40.35M-29.82M-24.22M-4.19M
EBITDA Margin %20.61%15%-5.35%-12.48%-71.39%-78.3%-152.99%-402.76%-1078.97%-541.33%-868.25%-673.91%-777.39%-175.36%-180.47%-60.05%-39.11%-41.9%-22.99%-175.05%-132.51%-705.97%-697.05%-13760.8%-
EBITDA Growth %221.79%563.53%47.3%69.2%-12.03%12.32%14.81%-9.51%-66.06%-18.87%-47.84%29.54%-375.2%31.31%-142.33%-27%7.1%-90.51%75.18%-149.66%11.57%-35.32%-23.13%-478.57%-
D&A (Non-Cash Add-back)55.43M55.66M56.67M54.05M44.47M47.57M74.44M54.37M6.43M13.37M15.13M19.05M11.93M10.23M9.04M5.13M4.94M5.99M5.73M4.08M3.81M3.12M2.44M838K36K
EBIT1.19B575.78M-235.52M-312.3M-971.02M-709.12M-771.1M-885.25M-760.67M-500.09M-424.59M-296.01M-184.21M-92.94M-63.57M-57.65M-43.74M-47.01M-24.66M-79.14M-39.5M-43.47M-32.26M-20.45M-4.22M
Net Interest Income-252.73M-141.16M-19.87M-25.66M-131.16M-141.44M-72.69M33.45M29.26M12.24M8.31M5.86M2.56M1.07M977K1.21M2.31M5.38M13.54M14.31M00000
Interest Income112.31M111.47M121.99M95.56M24.81M1.58M11.81M33.45M29.26M12.24M8.31M5.86M2.56M1.07M977K1.21M2.31M5.38M14.41M15.39M00000
Interest Expense365.05M252.63M141.86M121.22M155.97M143.02M84.5M00000000000872K1.08M00000
Other Income/Expense-121.19M-178.43M-200.49M-151.34M-341.92M-143.49M-27.16M54.18M54M9.21M14.48M5.93M4.38M1.02M12.87M-2.83M1.07M1.1M2.31M12.96M4.89M558K-390K-4.64M0
Pretax Income856.41M323.15M-377.38M-433.52M-1.13B-852.14M-855.6M-885.25M-760.67M-490.87M-410.11M-290.07M-400.6M-91.92M-116.59M-57.65M-43M-47.01M-25.53M-80.22M-34.61M-42.91M-35.37M-29.69M0
Pretax Margin %17.08%8.7%-16.79%-23.71%-108.63%-100.93%-173.6%-402.85%-1015.48%-545.95%-869.63%-705.83%-792.32%-194.88%-174.73%-69.66%-42.98%-46.76%-26.55%-157.61%-128.51%-750.77%-826.72%-16871.59%-
Income Tax-1.9B9.4M-99.22M6.72M4.16M680K2.68M863K823K000-40.21M-2.69M-10.57M0514K582K719K5.25M00390K-4.58M-86K
Effective Tax Rate %-221.76%2.91%26.29%-1.55%-0.37%-0.08%-0.31%-0.1%-0.11%0%0%0%10.04%2.93%9.07%0%-1.2%-1.24%-2.82%-6.54%0%0%-1.1%15.44%-
Net Income2.72B313.75M-278.16M-440.24M-1.13B-852.82M-858.28M-886.12M-761.5M-490.87M-410.11M-290.07M-360.39M-89.22M-106.01M-57.65M-43.52M-47.59M-26.25M-85.47M-34.61M-42.91M-32.65M-25.03M-4.14M
Net Margin %54.34%8.45%-12.37%-24.08%-109.04%-101.01%-174.15%-403.24%-1016.58%-545.95%-869.63%-705.83%-712.79%-189.17%-158.88%-69.66%-43.5%-47.34%-27.3%-167.92%-128.51%-750.77%-763.3%-14223.3%-
Net Income Growth %6153.27%212.79%36.82%61.08%-32.64%0.64%3.14%-16.36%-55.13%-19.69%-41.38%19.51%-303.92%15.84%-83.9%-32.48%8.56%-81.3%69.29%-146.95%19.36%-31.42%-30.44%-505.25%-
Net Income (Continuing)2.76B313.75M-278.16M-440.24M-1.13B-852.82M-858.28M-886.12M-761.5M-490.87M-410.11M-290.07M-360.39M-89.22M-106.01M-57.65M-43.52M-47.59M-26.25M-85.47M-34.61M-42.91M-32.65M-25.03M-4.14M
Discontinued Operations0000000000000000000000000
Minority Interest0000000000000000000000000
EPS (Diluted)19.742.33-2.18-3.52-9.30-7.20-7.46-8.11-7.57-5.42-4.79-3.45-4.85-1.45-2.11-1.36-1.04-1.14-0.64-2.21-1.09-1.96-2.75-26.56-12.48
EPS Growth %8150%206.88%38.07%62.15%-29.17%3.49%8.01%-7.13%-39.67%-13.15%-38.84%28.87%-234.48%31.28%-55.15%-30.77%8.77%-78.13%71.04%-102.75%44.39%28.73%89.65%-112.82%-
EPS (Basic)-2.39-2.18-3.52-9.30-7.20-7.46-8.11-7.57-5.42-4.79-3.45-4.85-1.45-2.11-1.36-1.04-1.14-0.64-2.21-1.09-1.96-2.75-26.56-12.48
Diluted Shares Outstanding138.04M134.68M127.65M124.91M121.69M118.45M114.99M109.26M100.59M90.55M85.6M83.99M74.28M61.55M50.29M42.41M42.04M41.63M41.08M38.66M31.89M21.95M11.89M942.66K331.34K
Basic Shares Outstanding133.83M131M127.65M124.91M121.69M118.45M114.99M109.26M100.59M90.55M85.6M83.99M74.28M61.55M50.29M42.41M42.04M41.63M41.08M38.66M31.89M21.95M11.89M942.66K331.34K
Dividend Payout Ratio-------------------------

Key Metrics

Growth RegimeExpanding
ProfitabilityModerate
Balance SheetStrained
Cash FlowImproving
Top Statement Risk

Leverage and pipeline funding dependence

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q3)

Revenue Compounding Driven by Commercial Franchises

Based on reported quarterly figures, ALNY's revenue climbed from roughly $594M in 2025Q1 to about $1.5B in 2026Q3, a trajectory that reflects a shift from collaboration-driven income toward recurring product sales that warrant durability scrutiny.

The revenue ramp is substantial, but the quarterly pattern shows lumpiness, with 2026Q3 spiking on what appears to be partner milestone or non-cash collaboration recognition rather than purely patient-driven demand. Investors should separate the run-rate of Amvuttra and Onpattro from one-time milestone income before extrapolating the growth rate. The durability of the top line depends on whether ATTR-cardiomyopathy new patient starts can sustain volume gains as the polyneuropathy base matures.

High Gross Margin Masks Operating Volatility

Reported gross margins near 75% to 88% across the period indicate strong product-level economics for ALNY, yet operating margin swung from roughly -17.7% to 29.5%, showing that gross profit strength has not consistently translated into bottom-line stability.

The gross margin profile is consistent with a specialized oligonucleotide franchise carrying low variable cost, which supports the platform thesis. However, the operating margin volatility suggests that R&D and SG&A absorb most incremental gross profit, leaving earnings highly sensitive to revenue timing. Margin durability will therefore hinge on whether recent operating profitability reflects structural leverage or simply a favorable milestone quarter.

Operating Leverage Emerging but Unproven

Operating income turned positive in several recent quarters, with 2026Q3 reaching roughly $345.8M against SG&A of about $342.0M, suggesting that operating expenses are beginning to be absorbed by gross profit growth in reported figures.

The fixed-cost base in R&D of roughly $364M to $413M per quarter remains large relative to operating income, so leverage is real only when revenue sustains above that threshold. Based on reported figures, SG&A has stabilized near $320M to $350M while revenue scaled, which is a constructive sign of overhead discipline. Investors should monitor whether this relationship holds through quarters where milestone income is absent.

Net Income Inflated by Non-Operating Items

Reported net income of $2.2B in 2026Q3 far exceeds operating income of $345.8M, and as reported in financial statements, this gap suggests that non-operating or tax-related items are driving EPS of $15.72 rather than core operations.

A net margin of 148.6% against an operating margin of 23.7% indicates that the headline earnings figure is not representative of recurring profitability. Stock-based compensation of roughly $70M to $110M per quarter also weighs on GAAP earnings quality and signals a meaningful non-cash cost. Analysts should normalize EPS for these items before comparing the period to the operating trend.

R&D Intensity Dominates the Cost Base

R&D expense held in a band of roughly $265M to $413M per quarter, against COGS that remained modest at about $67M to $361M, indicating that ALNY's cost structure is driven by pipeline investment rather than manufacturing scale.

The R&D line is the dominant cost driver, reflecting the expansion into large-population indications such as hypertension, which requires costlier late-stage trials. Management's ability to keep SG&A relatively flat while revenue rose is a meaningful expense discipline signal in reported figures. The cost structure implies that continued pipeline spending will keep operating margins sensitive to any slowdown in product revenue.

Milestone-Dependent Earnings Undermine the Narrative

Quarterly results show revenue and net income swings that may indicate partner milestones and non-cash collaboration income are supporting the headline growth rate rather than purely recurring product demand.

Short-side scrutiny would focus on the gap between 2026Q3 net income of $2.2B and a far smaller operating result, which may suggest earnings are not representative of underlying profitability. Elevated debt-to-equity of 1.62 alongside negative prior-period operating results warrants further investigation into how pipeline funding is sustained. If milestone income normalizes, the reported growth rate could decelerate sharply, a risk investors should weigh against the platform premium the market appears to assign.

ALNY — Frequently Asked Questions

Quick answers to the most common questions about buying ALNY stock.

What was Alnylam Pharmaceuticals, Inc.'s (ALNY) revenue in 2025?

For fiscal year 2025, Alnylam Pharmaceuticals, Inc. (ALNY) reported total revenue of $3.71B.

Is Alnylam Pharmaceuticals, Inc. (ALNY) profitable?

Alnylam Pharmaceuticals, Inc. (ALNY) is profitable, generating $313.7M in net income for the fiscal year ending 2025 with a net profit margin of 8.4%.

What is Alnylam Pharmaceuticals, Inc.'s operating profit margin?

Alnylam Pharmaceuticals, Inc. (ALNY) reported an operating income of $501.6M, resulting in an operating profit margin of 13.5%. This margin reflects the operational efficiency of the business before interest and taxes.

What is Alnylam Pharmaceuticals, Inc.'s gross profit and gross margin?

Alnylam Pharmaceuticals, Inc. (ALNY) generated $3.04B in gross profit for the year, representing a gross profit margin of 81.8%. This demonstrates the company's core pricing power and production efficiency.